Status:
UNKNOWN
Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Conditions:
Hepatitis C, Chronic
Fibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosi...
Detailed Description
Treatment of hepatitis C with interferon and ribavirin has a virological effect. Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic...
Eligibility Criteria
Inclusion
- Chronic viral hepatitis C, genotype 1 or 4
- Fibrosis F3 or F3-F4, assessed by the scoring Metavir system
- Initial treatment against HCV
Exclusion
- Psychiatric pathology
- Alcool consummation
- Pregnancy or plan of pregnancy
- Breastfeeding
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00148837
Start Date
September 1 2004
Last Update
February 8 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital du haut Leveque
Pessac, France, 33604